Wenxin Wang PhD, FRSC

Wenxin Wang is a Full Professor in Skin Research and Wound Healing, a Science Foundation Ireland (SFI) Principal Investigator at the Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), and a member of UCD Academic Council. He won the highly prestigious “Young Scientist Prize in Regenerative Medicine” in 2010 at the TERMIS-EU conference, the “SFI Principal Investigator award” in 2011, and the DEBRA Award for Excellent EB Patient Service in 2014, which highlight his work ethic and achievements. Prof. Wang’s scientific interests are in the areas of biomaterials, stem cell and gene therapy for the treatment of skin wounds, cartilage/bone regeneration, dental tissue regeneration, tissue sealant/adhesive.

His scientific contribution and achievements have been recognized both nationally and internationally including over 251 peer-reviewed scientific journal papers (Nat. Commun., Nat. Rev. Chem., Sci. Adv., Angew. Chem., JACS, Chem. Sci., and Nano Letters etc.), 5 book chapters, 34 patents, 174 conference abstracts and presentations, and 123 invited lectures and keynote presentations. Since 2009, he has graduated 27 PhD students and mentored over 29 postdoctoral researchers. His achievements have gained increased interest in the wider public community with publicity media activities (56 times in TV documentaries, videos, and Newspapers), for example, in RTE-TV, ‘The Sunday Times’, ‘The Irish Times’, ‘Science Daily’, and ‘Chemistry World’. He has been awarded significant funding (ca. 11.87 million Euros) from different sources, e.g., SFI, Health Research Board (HRB), Irish Research Council (IRC), Enterprise Ireland (EI), and European Union (EU-FP7 & EU Horizon 2020) to support his research activities.

Prof. Wang has acted as the symposium convener and chair, a member of the organizing committees, and a member of the conference advisory board for 34 international conferences and has been selected as an expert reviewer and panel member by 28 international research councils and funding bodies. As the founder, Prof Wang has launched 3 companies - Vornia Ltd (www.vornia.com, acquired by Ashland - a Fortune500 US company in Jan. 2018, renamed as Ashland Specialties Ireland), Blafar Ltd. (www.blafar.com), and Branca Bunús Ltd. (www.brancabunus.com). There three companies currently hire 25 employees in Ireland. Furthermore, he has 30 patents in collaboration with industry partners: Ashland, Amryt Biopharm, Blafar and Branca Bunús, and successfully launched and commercialized 5 newly developed technologies onto the market.